{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:42:17Z","timestamp":1793374937179,"version":"4.5.0"},"reference-count":223,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Hubei Province Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012554","name":"Hubei Provincial Department of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014206","name":"National Key Laboratory Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118201","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:04:28Z","timestamp":1782572668000},"page":"118201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases"],"prefix":"10.1016","volume":"252","author":[{"given":"Heng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-4226","authenticated-orcid":false,"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b0005","first-page":"669","article-title":"Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary","volume":"36","author":"The","year":"2023","journal-title":"Biomed. Environ. Sci."},{"issue":"25","key":"10.1016\/j.bcp.2026.118201_b0010","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10508","key":"10.1016\/j.bcp.2026.118201_b0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(25)01393-5","article-title":"Prioritising the primary prevention of heart failure","volume":"406","author":"Khan","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41392-025-02411-8","article-title":"Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction","volume":"10","author":"Garoffolo","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118201_b0025","article-title":"Creating an atlas of variant effects to resolve variants of uncertain significance and guide cardiovascular medicine","author":"Glazer","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hsc.13156","article-title":"Risk factors of deaths related to cardiovascular diseases in World Health Organization (WHO) member countries","volume":"30","author":"\u015eahin","year":"2022","journal-title":"Health Soc. Care Community"},{"key":"10.1016\/j.bcp.2026.118201_b0035","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with conventional Care in Patients with Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.bcp.2026.118201_b0055","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1161\/HYPERTENSIONAHA.123.21474","article-title":"Primary Aldosteronism in Chronic Kidney Disease: Blood pressure Control and Kidney and Cardiovascular Outcomes after Surgical Versus Medical Management","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40256-025-00723-2","article-title":"Mineralocorticoid Receptor Antagonism with Finerenone: a New Era in the Management of Patients with Heart failure with Mildly Reduced or Preserved Ejection Fraction","volume":"25","author":"Georgianos","year":"2025","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical Primary Aldosteronism and Cardiovascular Health: a Population-based Cohort Study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0070","doi-asserted-by":"crossref","DOI":"10.1530\/JME-21-0279","article-title":"Regulation of mineralocorticoid receptor activation by circadian protein TIMELESS","volume":"70","author":"Clyne","year":"2023","journal-title":"J. Mol. Endocrinol."},{"issue":"27","key":"10.1016\/j.bcp.2026.118201_b0075","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0080","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/aps.2013.187","article-title":"Ginsenoside Rg1 protects mouse podocytes from aldosterone-induced injury in vitro","volume":"35","author":"Mao","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118201_b0085","doi-asserted-by":"crossref","unstructured":"Nakamura, T., et al., Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney Int Suppl (2011), 2022. 12(1): p. 12-18.","DOI":"10.1016\/j.kisu.2021.11.004"},{"key":"10.1016\/j.bcp.2026.118201_b0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118201_b0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu. Rev. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1046\/j.1523-1755.2000.00971.x","article-title":"Brain mineralocorticoid receptors and centrally regulated functions","volume":"57","author":"de Kloet","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2026.118201_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.steroids.2014.05.018","article-title":"The neuronal mineralocorticoid receptor: from cell survival to neurogenesis","volume":"91","author":"Le Menuet","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.bcp.2026.118201_b0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.steroids.2014.04.005","article-title":"Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease","volume":"91","author":"Bene","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.bcp.2026.118201_b0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsbmb.2013.02.012","article-title":"Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity","volume":"137","author":"Feraco","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0120","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-25-0265","article-title":"Tissue-specific expression and regulation of the mineralocorticoid receptor during development","volume":"268","author":"Martinerie","year":"2026","journal-title":"J. Endocrinol."},{"issue":"24","key":"10.1016\/j.bcp.2026.118201_b0125","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jacc.2024.04.013","article-title":"Mineralocorticoid Receptor Antagonism in HeartFailure and ChronicKidneyDisease: Short-Term Pain for Long-Term Gain","volume":"83","author":"Ferro","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10505","key":"10.1016\/j.bcp.2026.118201_b0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(25)01153-5","article-title":"Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"406","author":"Pyne","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.bcp.2026.118201_b0140","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.jacc.2025.03.513","article-title":"Finerenone for Prevention of First-Detected AF across the Cardio-Kidney-Metabolic Spectrum: Insights from the FINE-HEART Pooled Analysis","volume":"85","author":"Piccini","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.bcp.2026.118201_b0145","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bcp.2026.118201_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110210","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: a systematic review and meta-analysis","volume":"195","author":"Chen","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bcp.2026.118201_b0160","article-title":"Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold","author":"Russo","year":"2025","journal-title":"Eur. J. Intern. Med."},{"issue":"27","key":"10.1016\/j.bcp.2026.118201_b0165","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2026.118201_b0170","article-title":"Effect of Finerenone in Cardiovascular and Renal Outcomes: a Systematic Review and Meta-analysis","author":"Rivera-Martinez","year":"2025","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the Nonsteroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.bcp.2026.118201_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312941","article-title":"Pharmacological Nephroprotection in Chronic Kidney Disease patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology","volume":"25","author":"Adamczak","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2026.118201_b0190","article-title":"Cardiovascular Outcomes and Hyperkalemia Risk in patients with Diabetes, Chronic Kidney Disease and Heart failure: a Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists","volume":"17","author":"Okunlola","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0195","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1038\/s41467-025-64640-3","article-title":"Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.118201_b0200","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.bcp.2026.118201_b0205","article-title":"Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis","volume":"12","author":"Yu","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.bcp.2026.118201_b0210","article-title":"Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5049\/EBP.2024.22.2.29","article-title":"Management strategies for Potassium Levels during Non-steroidal Mineralocorticoid Receptor Antagonist Therapy: a Comprehensive Review","volume":"22","author":"Son","year":"2024","journal-title":"Electrolyte Blood Press"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0220","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000550850","article-title":"Finerenone in chinese patients with Chronic Kidney Disease and Type 2 Diabetes: a FIDELITY Subgroup Analysis","volume":"12","author":"Li","year":"2026","journal-title":"Kidney Dis (basel)"},{"issue":"16","key":"10.1016\/j.bcp.2026.118201_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems","volume":"23","author":"Kolkhof","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/molecules30061226","article-title":"In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics","volume":"30","author":"Liang","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118201_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2024.109524","article-title":"Patterns of corticosterone exposure affect the subcellular localisation of mineralocorticoid and glucocorticoid receptor complexes and gene expression","volume":"214","author":"Paul","year":"2025","journal-title":"Steroids"},{"issue":"36","key":"10.1016\/j.bcp.2026.118201_b0240","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone Impedes Aldosterone-dependent Nuclear import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0245","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2014.01.125","article-title":"Genome-wide analysis of murine renal distal convoluted tubular cells for the target genes of mineralocorticoid receptor","volume":"445","author":"Ueda","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0250","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1161\/HYPERTENSIONAHA.122.19213","article-title":"Mechanism by which Inflammation and Oxidative stress Induce Mineralocorticoid Receptor Gene Expression in Aging Vascular Smooth Muscle Cells","volume":"80","author":"Ibarrola","year":"2023","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051343","article-title":"The Pillars for Renal Disease Treatment in patients with Type 2 Diabetes","volume":"15","author":"Kearney","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118201_b0260","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-981-13-8871-2_15","article-title":"Role of Aldosterone in Renal Fibrosis","volume":"1165","author":"Shrestha","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0265","doi-asserted-by":"crossref","first-page":"H1318","DOI":"10.1152\/ajpheart.00415.2024","article-title":"Temporal mineralocorticoid receptor activation regulates the molecular clock and transcription of cardiovascular disease modulators in myeloid cells","volume":"328","author":"Heanue","year":"2025","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0270","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","author":"Le Billan","year":"2021","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/cells14050337","article-title":"Finerenone Alleviates Over-Activation of Complement C5a-C5aR1 Axis of Macrophages by Regulating G Protein Subunit Alpha i2 to Improve Diabetic Nephropathy","volume":"14","author":"Li","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0280","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11906-025-01337-4","article-title":"Sympathetic nervous System in Heart failure: Targets for Treatments","volume":"27","author":"Arshad","year":"2025","journal-title":"Curr. Hypertens. Rep."},{"issue":"19","key":"10.1016\/j.bcp.2026.118201_b0285","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1021\/acs.jcim.2c00788","article-title":"Intermolecular Interactions in G Protein-coupled Receptor Allosteric Sites at the Membrane Interface from Molecular Dynamics Simulations and Quantum Chemical Calculations","volume":"62","author":"Ding","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bcp.2026.118201_b0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart failure and Cardiorenal Diseases: Comparison at Bench and Bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b0295","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0300","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042069","article-title":"Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats","volume":"22","author":"Rahman","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0310","doi-asserted-by":"crossref","first-page":"H303","DOI":"10.1152\/ajpheart.00545.2023","article-title":"Fibroblasts and immune cells: at the crossroad of organ inflammation and fibrosis","volume":"326","author":"Smolgovsky","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bcp.2026.118201_b0315","article-title":"Injectable BMSC-Based Extracellular Matrix-Mimicking Microtissue for Myocardial Infarction Repair","author":"Yao","year":"2025","journal-title":"Adv Sci (weinh)"},{"key":"10.1016\/j.bcp.2026.118201_b0320","article-title":"Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by \u03b2-Adrenergic Activation","author":"Xu","year":"2025","journal-title":"Adv Sci (weinh)"},{"key":"10.1016\/j.bcp.2026.118201_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115975","article-title":"Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR","volume":"220","author":"Zhou","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0330","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease","volume":"13","author":"Ixchel","year":"2024","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0335","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.7150\/thno.124140","article-title":"Impairment of mitochondrial quality control exacerbates diabetes-related atrial fibrillation by cGAS-STING signaling pathway and cardiomyocyte-macrophage crosstalk","volume":"16","author":"Meng","year":"2026","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0340","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13850","article-title":"Reduction in Acetylation of Superoxide Dismutase 2 in Skeletal Muscle Improves Exercise Capacity in mice with Heart failure","volume":"16","author":"Masunaga","year":"2025","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b0345","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/CIRCRESAHA.124.324909","article-title":"Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood pressure via Attenuation of EndMT in Hypertensive mice","volume":"137","author":"Pernomian","year":"2025","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12951-025-03232-1","article-title":"ROS-responsive simvastatin nano-prodrug based on tertiary amine-oxide zwitterionic polymer for atherosclerotic therapy","volume":"23","author":"Yang","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.bcp.2026.118201_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102946","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy","volume":"68","author":"Yao","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2026.118201_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115661","article-title":"Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors","volume":"168","author":"Sanz-G\u00f3mez","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118201_b0365","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118201_b0370","article-title":"Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2\/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b0375","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamacardio.2025.1775","article-title":"Finerenone according to Frailty in Heart failure: a Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial","volume":"10","author":"Butt","year":"2025","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0380","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2400541","article-title":"Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China","volume":"46","author":"Zhou","year":"2024","journal-title":"Ren. Fail."},{"key":"10.1016\/j.bcp.2026.118201_b0385","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3569","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis","author":"Mentz","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2026.118201_b0390","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2509542","article-title":"Increasing the Potassium Level in patients at High Risk for Ventricular Arrhythmias","author":"J\u00f8ns","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0395","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and Cardiorenal Outcomes with Finerenone in Chronic Kidney Disease in Type 2 Diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.108981","article-title":"Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors\/SGLT-2i","volume":"39","author":"Liu","year":"2025","journal-title":"J. Diabetes Complications"},{"issue":"7","key":"10.1016\/j.bcp.2026.118201_b0405","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000543923","article-title":"Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in patients Initiating Finerenone in the USA: a Cohort Study from the FOUNTAIN Platform","volume":"149","author":"Kovesdy","year":"2025","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0410","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","article-title":"Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","volume":"24","author":"Shokravi","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0415","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2026.118201_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156572","article-title":"From mechanism to clinic: a call for actionable strategies to optimize finerenone and SGLT2i complementary therapy in T2DM-related CKD","volume":"179","author":"Cui","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.bcp.2026.118201_b0425","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfag042","article-title":"Finerenone with Empagliflozin in CKD with diabetes (CONFIDENCE): only a blood pressure effect? likely!","author":"Soler","year":"2026","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0430","article-title":"A FIDELITY Analysis on Finerenone with SGLT-2i and GLP-1RA in CKD","volume":"11","author":"Singh","year":"2026","journal-title":"Kidney Int Rep"},{"issue":"24","key":"10.1016\/j.bcp.2026.118201_b0435","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1042\/CS20256132","article-title":"Deficiency of mineralocorticoid receptor signalling in myeloid cells protects cardiac and kidney function in hypertensive diabetic mice","volume":"139","author":"Tesch","year":"2025","journal-title":"Clin. Sci. (Lond.)"},{"issue":"11","key":"10.1016\/j.bcp.2026.118201_b0440","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ejhf.3453","article-title":"The Spironolactone Initiation Registry Randomized Interventional Trial in Heart failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design","volume":"26","author":"Lund","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118201_b0445","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b0450","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2024.10510","article-title":"Dapagliflozin for Critically Ill patients with Acute Organ Dysfunction: the DEFENDER Randomized Clinical Trial","volume":"332","author":"Tavares","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.118201_b0455","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078483","article-title":"SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study","volume":"385","author":"Fu","year":"2024","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0460","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: the FIDELITY Analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.bcp.2026.118201_b0465","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/HJH.0000000000003836","article-title":"Advanced progress of the relationship between renin-angiotensin-aldosterone system inhibitors and cancers","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Hypertens."},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309973","article-title":"Assessing the quality of CKD care using process quality indicators: a scoping review","volume":"19","author":"Zhou","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0475","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and their Role in Influencing Heart failure Outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.bcp.2026.118201_b0480","first-page":"1460","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and risk of Hyperkalemia in people with Type 2 Diabetes: a Meta-Analysis of Individual Participant Data from Randomized","volume":"145","author":"Neuen","year":"2022","journal-title":"Controlled Trials. Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032334","article-title":"Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy","volume":"24","author":"Jerome","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118201_b0490","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.044798","article-title":"Cardioprotective Effects of Finerenone Associated with the suppression of Myocardial Sodium Accumulation in Aldosterone\/Salt-Loaded Rats","author":"Rahman","year":"2026","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2026.118201_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2026.116448","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates diabetic nephropathy via suppressing SLC7A11-mediated ferroptosis","volume":"175","author":"Yu","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118201_b0500","article-title":"Effect of finerenone on renal function in patients with type 2 diabetic nephropathy: a retrospective cohort study","volume":"17","author":"Liu","year":"2026","journal-title":"Front Endocrinol (lausanne)"},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032536","article-title":"Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart failure with Preserved Ejection Fraction","volume":"24","author":"Lima-Posada","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2026.118201_b0510","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0515","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/s41467-023-38958-9","article-title":"Signaling mechanisms in renal compensatory hypertrophy revealed by multi-omics","volume":"14","author":"Kikuchi","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0520","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","article-title":"Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus","volume":"15","author":"Jin","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0525","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4330\/wjc.v14.i4.220","article-title":"GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone","volume":"14","author":"Pollard","year":"2022","journal-title":"World J. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0530","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41440-025-02175-2","article-title":"Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD","volume":"48","author":"Sato","year":"2025","journal-title":"Hypertens. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0535","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","article-title":"Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction after Myocardial Infarction","volume":"67","author":"Gueret","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2026.118201_b0540","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082071","article-title":"Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline","volume":"390","author":"Agarwal","year":"2025","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b0545","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s10741-025-10520-3","article-title":"The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment","volume":"30","author":"Taub","year":"2025","journal-title":"Heart Fail. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0550","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","article-title":"Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists","volume":"45","author":"Marzolla","year":"2022","journal-title":"J. Endocrinol. Invest."},{"issue":"10","key":"10.1016\/j.bcp.2026.118201_b0555","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11906-018-0887-6","article-title":"Mineralocorticoids and Cardiovascular Disease in Females with Insulin Resistance and Obesity","volume":"20","author":"Nayyar","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.bcp.2026.118201_b0560","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0565","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/dom.15305","article-title":"Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: a FIDELITY subgroup analysis","volume":"26","author":"Perakakis","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.bcp.2026.118201_b0570","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.4239\/wjd.v14.i9.1334","article-title":"MicroRNA-155 mediates endogenous angiotensin II type 1 receptor regulation: implications for innovative type 2 diabetes mellitus management","volume":"14","author":"Papadopoulos","year":"2023","journal-title":"World J. Diabetes"},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b0575","first-page":"745","article-title":"Efficacy and Safety of Finerenone in Type 2 Diabetes: a Pooled Analysis of Trials of Heart failure and Chronic Kidney Disease","volume":"48","author":"Ostrominski","year":"2025","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.bcp.2026.118201_b0580","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14186355","article-title":"Finerenone Versus Placebo on Renal Outcomes in patients with Chronic Kidney Disease and Type 2 Diabetes: a Systematic Review and Meta-Analysis","volume":"14","author":"Diaz","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2026.118201_b0585","article-title":"Association of finerenone with prognosis and safety in diabetic kidney disease patients: an undated meta-analysis based on four RCTs","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med (lausanne)"},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0590","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ajhp\/zxaf044","article-title":"KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: a primer on what pharmacists need to know","volume":"82","author":"Awdishu","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bcp.2026.118201_b0595","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1320603","article-title":"Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (lausanne)"},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0600","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.041","article-title":"Efficacy and Safety of Finerenone in Heart failure with Preserved Ejection Fraction: a FINE-HEART Analysis","volume":"13","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0610","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jjcc.2025.06.013","article-title":"Finerenone and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: a propensity-matched analysis","volume":"86","author":"Calcagno","year":"2025","journal-title":"J. Cardiol."},{"key":"10.1016\/j.bcp.2026.118201_b0615","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1725782","article-title":"Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0620","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13098-024-01466-x","article-title":"Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms","volume":"16","author":"Wang","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0625","first-page":"135","article-title":"Finerenone for diabetic hearts: a critical appraisal of MACE benefits and the research road ahead","volume":"12","author":"Dong","year":"2026","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.bcp.2026.118201_b0630","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.yjmcc.2025.06.013","article-title":"Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management","volume":"206","author":"Chen","year":"2025","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118201_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102615","article-title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials","volume":"49","author":"Pamporis","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.bcp.2026.118201_b0640","article-title":"Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118201_b0645","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15093486","article-title":"Finerenone across the Cardiovascular-Kidney-Metabolic Continuum: from Mechanistic Rationale to Clinical Positioning-a Narrative Review","volume":"15","author":"Kubica","year":"2026","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0650","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J. Hypertens."},{"issue":"Supplement_1","key":"10.1016\/j.bcp.2026.118201_b0655","doi-asserted-by":"crossref","DOI":"10.2337\/db24-878-P","article-title":"878-P: effect of Finerenone on Resistant Hypertension in Type 2 Diabetes Mellitus\u2014A Randomized Controlled Trial in Indian Population","volume":"73","author":"Gadve, s.s.,","year":"2024","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.bcp.2026.118201_b0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0665","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076444","article-title":"Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials","volume":"14","author":"Bansal","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.bcp.2026.118201_b0670","article-title":"Finerenone combined with guideline-directed medical therapy in patients with post-myocardial infarction heart failure: a real-world study","volume":"17\u20132026","author":"Zhao","year":"2026","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0675","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone Reduces New-Onset Atrial Fibrillation in patients with Chronic Kidney Disease and Type 2 Diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0680","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeag077","article-title":"Finerenone vs. spironolactone to reduce adverse outcomes in patients with cardiac\u2013kidney\u2013metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin atrial fibrillation project","volume":"6","author":"Tian","year":"2026","journal-title":"European Heart Journal Open"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0685","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ehf2.14962","article-title":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes","volume":"12","author":"Filippatos","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0690","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and Safety of Finerenone across the Ejection Fraction Spectrum in Heart failure with Mildly Reduced or Preserved Ejection Fraction: a Prespecified Analysis of the FINEARTS-HF Trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0695","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jdi.70023","article-title":"Effectiveness of finerenone in chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: a retrospective real-world study","volume":"16","author":"Wu","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"24","key":"10.1016\/j.bcp.2026.118201_b0700","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0705","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.bcp.2026.118201_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102638","article-title":"Finerenone in diabetic kidney disease: a systematic review and critical appraisal","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"issue":"21","key":"10.1016\/j.bcp.2026.118201_b0715","first-page":"2171","article-title":"Finerenone in Type 1 Diabetes and Chronic Kidney Disease","volume":"394","author":"Granata","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0720","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cvr\/cvae070","article-title":"Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model","volume":"121","author":"Mira Hernandez","year":"2025","journal-title":"Cardiovasc. Res."},{"issue":"10458","key":"10.1016\/j.bcp.2026.118201_b0725","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.bcp.2026.118201_b0730","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118201_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)01009-3","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)","author":"Neuen","year":"2026","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0740","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCRESAHA.125.326303","article-title":"Exercise Mitigates Diabetic Cardiomyopathy by Suppressing Ferroptosis via N-Acetyltransferase 10","volume":"137","author":"Shen","year":"2025","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118201_b0745","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.123.065603","article-title":"USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart","volume":"149","author":"Xie","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2026.118201_b0750","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jare.2023.08.015","article-title":"Triad3A-mediated K48-Linked ubiquitination and degradation of TLR9 impairs mitochondrial bioenergetics and exacerbates diabetic cardiomyopathy","volume":"61","author":"Kong","year":"2024","journal-title":"J. Adv. Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0755","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s42255-024-01036-5","article-title":"Inhibition of fatty acid uptake by TGR5 prevents diabetic cardiomyopathy","volume":"6","author":"Wang","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.bcp.2026.118201_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156062","article-title":"Targeting endoplasmic reticulum stress as a potential therapeutic strategy for diabetic cardiomyopathy","volume":"162","author":"Congur","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.bcp.2026.118201_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155658","article-title":"PRDM16 exerts critical role in myocardial metabolism and energetics in type 2 diabetes induced cardiomyopathy","volume":"146","author":"Hu","year":"2023","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0770","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7150\/ijbs.65938","article-title":"Neuraminidase 1 deficiency attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory via AMPK-SIRT3 pathway in diabetic cardiomyopathy mice","volume":"18","author":"Guo","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0775","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41401-024-01247-2","article-title":"Macrod1 suppresses diabetic cardiomyopathy via regulating PARP1-NAD(+)-SIRT3 pathway","volume":"45","author":"Liu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118201_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105268","article-title":"NR4A3 prevents diabetes induced atrial cardiomyopathy by maintaining mitochondrial energy metabolism and reducing oxidative stress","volume":"106","author":"Peng","year":"2024","journal-title":"EBioMedicine"},{"issue":"34","key":"10.1016\/j.bcp.2026.118201_b0785","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/eurheartj\/ehaf316","article-title":"Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial","volume":"46","author":"Berger","year":"2025","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0790","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone Reduces risk of Incident Heart failure in patients with Chronic Kidney Disease and Type 2 Diabetes: analyses from the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0795","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2026.118201_b0800","article-title":"Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations","author":"Heerspink","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b0805","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/imj.15253","article-title":"Temporal trends in the burden of heart failure","volume":"51","author":"Chan","year":"2021","journal-title":"Intern. Med. J."},{"issue":"13","key":"10.1016\/j.bcp.2026.118201_b0810","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/CIRCULATIONAHA.125.075150","article-title":"Targeting Calcium Regulation for Heart failure and Arrhythmia Therapeutics: a critical Review","volume":"152","author":"Redel-Traub","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0815","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000539393","article-title":"Exploring the Mechanism of Cardiorenal Protection with Finerenone based on Network Pharmacology","volume":"14","author":"Si","year":"2024","journal-title":"Cardiorenal Med"},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0820","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0825","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/s41467-024-48970-2","article-title":"Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5\/NR4a1 axis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0830","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11427-021-1945-6","article-title":"Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction","volume":"65","author":"Ke","year":"2022","journal-title":"Sci. China Life Sci."},{"issue":"10","key":"10.1016\/j.bcp.2026.118201_b0835","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium Zirconium Cyclosilicate for Management of Hyperkalemia during Spironolactone Optimization in patients with HeartFailure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0840","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118201_b0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, evidence, and Unanswered questions","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.bcp.2026.118201_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156297","article-title":"Use of finerenone in patients with chronic kidney disease at high risk of heart failure","volume":"169","author":"Hakim","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.bcp.2026.118201_b0855","unstructured":"Lam, C.S.P., et al., Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. JACC Heart Fail, 2026: p. 102943."},{"key":"10.1016\/j.bcp.2026.118201_b0860","doi-asserted-by":"crossref","DOI":"10.1093\/ejhf\/xuag025","article-title":"Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy","author":"Yoon","year":"2026","journal-title":"Eur. J. Heart Fail."},{"issue":"7","key":"10.1016\/j.bcp.2026.118201_b0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167968","article-title":"Finerenone ameliorates high-fat-induced myocardial lipotoxicity by suppressing ferroptosis through augmenting the system Xc(-)\/GSH synthesis pathway","volume":"1871","author":"Xu","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0870","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of Finerenone on the KCCQ inPatients with HFmrEF\/HFpEF: aPrespecifiedAnalysisofFINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b0875","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese patients with Worsening Chronic Heart failure and Diabetes and\/or Chronic Kidney Disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0880","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b0885","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jacc.2025.06.036","article-title":"Evidentiary Landscape of Heart failure Therapies, Regulatory Decisions, and translation into guidelines","volume":"86","author":"Kaul","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"19","key":"10.1016\/j.bcp.2026.118201_b0890","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196285","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease","volume":"12","author":"Shah","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2026.118201_b0895","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.15420\/cfr.2024.11","article-title":"Finerenone: will it Be a Game-changer?","volume":"10","author":"Khullar","year":"2024","journal-title":"Card. Fail. Rev."},{"key":"10.1016\/j.bcp.2026.118201_b0900","doi-asserted-by":"crossref","DOI":"10.1093\/ejhf\/xuag030","article-title":"Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial","author":"Hamatani","year":"2026","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcp.2026.118201_b0905","doi-asserted-by":"crossref","DOI":"10.1093\/ejhf\/xuag008","article-title":"Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial","author":"Chimura","year":"2026","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0910","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1002\/ehf2.15294","article-title":"SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper","volume":"12","author":"Ferreira","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"39","key":"10.1016\/j.bcp.2026.118201_b0915","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"issue":"4s","key":"10.1016\/j.bcp.2026.118201_b0920","first-page":"S117","article-title":"2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kdigo","year":"2024","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0925","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15450","article-title":"Current management of chronic kidney disease in type-2 diabetes-a tiered approach: an overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines","volume":"42","author":"Dasgupta","year":"2025","journal-title":"Diabet. Med."},{"key":"10.1016\/j.bcp.2026.118201_b0930","unstructured":"Expert Group of the Multidisciplinary Expert Consensus on Clinical Application of Nonailis (2025 Edition). Chinese Journal of Diabetes, 2025. 17(11): p. 1427-1437."},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b0935","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2337\/dc23-1420","article-title":"Outcomes with Finerenone in patients with Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance","volume":"47","author":"Ebert","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b0940","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.mce.2011.07.035","article-title":"Structural determinants of ligand binding to the mineralocorticoid receptor","volume":"350","author":"Huyet","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118201_b0945","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032971","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease","volume":"13","author":"Lima Posada","year":"2024","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b0950","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000506275","article-title":"Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Fr\u00f6mter Rats, a Genetic Model of Chronic Kidney Disease","volume":"51","author":"Gil-Ortega","year":"2020","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b0955","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12933-025-03014-x","article-title":"Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)","volume":"24","author":"Tanaka","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118201_b0960","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/clc.23261","article-title":"Eplerenone in patients with myocardial infarction and \u201cmid-range\u201d ejection fraction: an analysis from the EPHESUS trial","volume":"42","author":"Ferreira","year":"2019","journal-title":"Clin. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0965","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.117.09791","article-title":"Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) is involved in Cardiac Remodeling after Myocardial Infarction through NF\u03baB Pathway","volume":"70","author":"Mart\u00ednez-Mart\u00ednez","year":"2017","journal-title":"Hypertension"},{"issue":"16","key":"10.1016\/j.bcp.2026.118201_b0970","doi-asserted-by":"crossref","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b0975","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/HYPERTENSIONAHA.120.16909","article-title":"Time-Dependent risk of Atrial Fibrillation in patients with Primary Aldosteronism after Medical or Surgical Treatment Initiation","volume":"77","author":"Kim","year":"2021","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.bcp.2026.118201_b0980","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1248\/bpb.b24-00445","article-title":"Aldosterone Robustly Promotes Atrial Fibrillation in the Presence of Chronic volume Overload in Rats","volume":"47","author":"Aimoto","year":"2024","journal-title":"Biol. Pharm. Bull."},{"issue":"7","key":"10.1016\/j.bcp.2026.118201_b0985","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamacardio.2025.0848","article-title":"Finerenone and Atrial Fibrillation in Heart failure: a Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial","volume":"10","author":"Matsumoto","year":"2025","journal-title":"JAMA Cardiol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118201_b0990","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/HJH.0000000000002067","article-title":"Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation","volume":"37","author":"Araos","year":"2019","journal-title":"J. Hypertens."},{"issue":"18","key":"10.1016\/j.bcp.2026.118201_b0995","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild patients Hospitalization and SurvIval Study in Heart failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b1000","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s00392-023-02349-3","article-title":"Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis","volume":"113","author":"Sampaio Rodrigues","year":"2024","journal-title":"Clin. Res. Cardiol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118201_b1005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/eurheartj\/ehad811","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials","volume":"45","author":"Oraii","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2026.118201_b1010","article-title":"Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment","author":"Peikert","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2026.118201_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117366","article-title":"Chronic inhibition of cGMP-specific phosphodiesterase 5 attenuates myocardial hypertrophy by promoting mitophagy in cardiomyocytes","author":"Zhang","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118201_b1020","article-title":"Unveiling Clinical and Genetic Distinctions in Pure-Apical Versus Distal-Dominant Apical Hypertrophic Cardiomyopathy","volume":"14","author":"Sugiura","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2026.118201_b1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.104191","article-title":"Mineralocorticoid receptor regulates vascular damage by inducing autophagy in mice with obesity and hypertension","author":"Wang","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"10.1016\/j.bcp.2026.118201_b1030","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ejhf.3694","article-title":"Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"27","author":"Cunningham","year":"2025","journal-title":"Eur. J. Heart Fail."},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b1035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in pressure Overload-induced Cardiac Hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b1040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ndt\/gfaf183","article-title":"Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations","volume":"41","author":"Heerspink","year":"2026","journal-title":"Nephrol. Dial. Transplant."},{"issue":"31","key":"10.1016\/j.bcp.2026.118201_b1045","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118201_b1050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12933-023-01928-y","volume":"22","author":"Tanaka","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2026.118201_b1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177826","article-title":"Therapeutic effects of finerenone and exenatide on diabetes-induced heart failure: a combined approach targeting inflammation and oxidative stress","volume":"1002","author":"Ko\u00e7ak","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118201_b1060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.steroids.2005.09.017","article-title":"Nongenomic actions of aldosterone: physiological or pathophysiological role?","volume":"71","author":"Mihailidou","year":"2006","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b1065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/er.2005-0004","article-title":"The nongenomic actions of aldosterone","volume":"26","author":"Funder","year":"2005","journal-title":"Endocr. Rev."},{"issue":"18","key":"10.1016\/j.bcp.2026.118201_b1070","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.70062","article-title":"Role of L-type Ca(2+)-channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue","volume":"12","author":"Schinzari","year":"2024","journal-title":"Physiol. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b1075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2026.118201_b1080","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00136.2025","article-title":"The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation","author":"Myakala","year":"2025","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118201_b1085","article-title":"Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: a review","volume":"15","author":"Alkhatib","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2026.118201_b1090","article-title":"Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med (lausanne)"},{"key":"10.1016\/j.bcp.2026.118201_b1095","article-title":"Clinical efficacy of probiotics in the treatment of diabetes kidney disease: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118201_b1100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MNH.0000000000001089","article-title":"Aldosterone synthase inhibition in chronic kidney disease","volume":"34","author":"Theodorakopoulou","year":"2025","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"11","key":"10.1016\/j.bcp.2026.118201_b1105","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s40265-025-02229-2","article-title":"Aldosterone synthase inhibitors for resistant hypertension: pharmacological insights - a systematic review","volume":"85","author":"Cicero","year":"2025","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b1110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MNH.0000000000001067","article-title":"Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors","volume":"34","author":"Helmeczi","year":"2025","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"3","key":"10.1016\/j.bcp.2026.118201_b1115","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cardfail.2025.05.002","article-title":"Mineralocorticoid receptor antagonists and aldosterone synthase inhibitors: agent comparison with implications for clinical practice and trial design","volume":"32","author":"Ferreira","year":"2026","journal-title":"J. Card. Fail."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600540X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600540X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:21:34Z","timestamp":1786652494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600540X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":223,"alternative-id":["S000629522600540X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118201","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118201"}}